New targeted drug enters human trials for multiple advanced cancers
NCT ID NCT04180371
Summary
This early-stage study is testing a new drug called BT5528, both alone and combined with another cancer drug (nivolumab), in people with advanced solid tumors. The main goals are to find a safe dose and see what side effects occur. Researchers will also check if the drug helps shrink or control tumors in cancers like ovarian, lung, breast, and bladder cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Antwerp University Hospital (UZA)
Edegem, Belgium
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
California Cancer Associates for Research and Excellence, Inc.
Encinitas, California, 92024, United States
-
Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Centro Integral Oncologico Clara Campal
Madrid, 28050, Spain
-
Cliniques Universitaires Saint-Luc
Brussels, Belgium
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, New York, 10021, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Gachon University Gil Medical Center
Incheon, 21565, South Korea
-
Hospital Fundación Jimenez Diaz
Madrid, 28040, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 8035, Spain
-
Institut Catala d'Oncologia - L'Hospitalet
Barcelona, 08908, Spain
-
Institut Jules Bordet
Brussels, 1070, Belgium
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sarah Cannon Research Institute UK
London, United Kingdom, W1G 6AD, United Kingdom
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon and HCA Research Institute
Nashville, Tennessee, 37221, United States
-
Severance Hospital, Yonsei University Health System
Seoul, 3722, South Korea
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
Sir Bobby Robson Cancer Trials Research Centre, The Northern Center for Cancer Care, Freeman Hospital
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Stephenson Cancer Center (Oklahoma University)
Oklahoma City, Oklahoma, 73104, United States
-
The Christie NHS Foundation Trust
Manchester, United Kingdom, M20 4BX, United Kingdom
-
The Leeds Teaching Hospitals NHS Trust Of Trust Headquarters, St James's University Hospital
Leeds, LS9 7TF, United Kingdom
-
Universitair Ziekenhuis Gent (UZ)
Ghent, 9000, Belgium
-
University of California - Irvine Medical Center
Orange, California, 92868, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.